Jazz Pharma falls as lung cancer drug fails late-stage survival goal

Jazz Pharmaceuticals

12/06/2026 14:06

** Shares of drugmaker Jazz Pharmaceuticals JAZZ.O fall 2% to $232.01 premarket
** Co says Zepzelca failed to help patients with relapsed small cell lung cancer, an aggressive form of lung cancer that spreads quickly, live longer in a late-stage study
** Says study tested Zepzelca alone and with chemotherapy irinotecan vs standard treatment in patients whose cancer had returned
** Co's Zepzelca alone showed median survival of 8.7 months vs 10.7 months for standard care; combo arm 10.9 months, co says
** Says differences were not statistically meaningful; no new safety issues seen
** Co says results will not impact 2026 forecast; to discuss data with FDA
** As of last close, LIXT stock up ~39% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))